Latest News
SUBSEQUENT DECISION NOT TO RECOMMEND MAVENCLAD®
23rd April 2018
The Pharmaceutical Benefits Advisory Committee (PBAC) have announced they have not recommended the listing of MAVENCLAD® (cladribine tablets) for relapsing remitting MS (RRMS) on the Pharmaceutical Benefits Scheme (PBS).
MSWA supporting people living with Parkinson’s
11th April 2018
For two years Kent Piercy developed an increasing stiffness and slowness in both arms and a reduced swing in his right arm. Naturally concerned about these changes, Kent saw a neurologist early last year, and at the age of 74 was diagnosed with tremor-dominant idiopathic Parkinson’s.
Read More
New UV research gives hope to people with MS
14th March 2018
31-year-old Chloe Baker has been living with MS and embracing the everyday challenges that comes with that diagnosis. For Chloe and many others with MS in Perth and around the world, the research by Perth-based researcher Professor Prue Hart is giving them hope. In a world-first, the research has proven to delay the development of MS in high-risk individuals using narrowband UVB treatment.
Read More
$1 million research funding into brain plasticity
12th March 2018
MSWA has recognised the importance of the cutting-edge research being carried out by Associate Professor Jenny Rodger and is investing $1 million to fund her work over the next four years, in her new role as the Senior Research Fellow in Brain Plasticity at the Perron Institute. Jenny and her team will carry out research to understand the mechanisms of brain plasticity to improve the quality of life in patients with neurological conditions.
Read More
